These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 19115513)
1. Erlotinib for the treatment of non-small-cell lung cancer. Boysen M; Longson C; Stevens A Lancet Oncol; 2009 Jan; 10(1):15-6. PubMed ID: 19115513 [No Abstract] [Full Text] [Related]
2. Erlotinib in lung cancer. Pao W; Ladanyi M; Miller VA; N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16240471 [No Abstract] [Full Text] [Related]
3. NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer. Rinaldi F; George E; Clark P Lancet Oncol; 2011 Aug; 12(8):728-30. PubMed ID: 21928488 [No Abstract] [Full Text] [Related]
8. [Erlotinib in non-small cell lung cancer]. Takeda M; Okamoto I Gan To Kagaku Ryoho; 2011 Jun; 38(6):896-900. PubMed ID: 21677478 [TBL] [Abstract][Full Text] [Related]
9. Lung cancer response to gefitinib, then erlotinib, then gefitinib again. Wong AS; Seto KY; Chin TM; Soo RA J Thorac Oncol; 2008 Sep; 3(9):1077-8. PubMed ID: 18758318 [No Abstract] [Full Text] [Related]
10. Wood-smoke exposure as a response and survival predictor in erlotinib-treated nonsmall cell lung cancer patients. Arrieta O; Rios Trejo MA; Michel RM J Thorac Oncol; 2009 Aug; 4(8):1043. PubMed ID: 19633484 [No Abstract] [Full Text] [Related]
12. VeriStrat validated in patients with non-small-cell lung cancer. Butts CA Lancet Oncol; 2014 Jun; 15(7):671-2. PubMed ID: 24831978 [No Abstract] [Full Text] [Related]
13. Erlotinib in patient with non-small cell lung cancer: significant symptomatic improvement within a few days but without change in chest X-ray. Garfield D; Kashef G Lung Cancer; 2006 Mar; 51(3):389-90. PubMed ID: 16359750 [No Abstract] [Full Text] [Related]
14. KRAS wild-type lung cancer: a moving target in an era of genotype migration. Oxnard GR; Jänne PA J Clin Oncol; 2012 Sep; 30(27):3322-4. PubMed ID: 22869875 [No Abstract] [Full Text] [Related]
16. Comparison is beyond IPASS and OPTIMAL. Lam KC; Mok TS Hong Kong Med J; 2014 Jun; 20(3):176-7. PubMed ID: 24914076 [No Abstract] [Full Text] [Related]
17. Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure. Gridelli C; Maione P; Galetta D; Rossi A J Thorac Oncol; 2007 Jan; 2(1):96-8. PubMed ID: 17410020 [No Abstract] [Full Text] [Related]
18. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. Hata A; Kaji R; Fujita S; Katakami N J Thorac Oncol; 2011 Mar; 6(3):653-4. PubMed ID: 21317753 [No Abstract] [Full Text] [Related]
19. Compassionate use programs or phase IV trials of innovative molecular targeted drugs in lung cancer: deal or no deal? Eberhardt W J Thorac Oncol; 2010 Oct; 5(10):1495-7. PubMed ID: 20871257 [No Abstract] [Full Text] [Related]
20. An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer. Toh CK; Lee P; Chowbay B; Goh JW; Mancer K; Tan PH Acta Oncol; 2007; 46(2):256-8. PubMed ID: 17453379 [No Abstract] [Full Text] [Related] [Next] [New Search]